The Covid-19 antibody therapy -- AZD7442 -- was only 33 per cent effective in reducing the risk of symptoms, when compared to a placebo, according to the results of a Phase 3 trial.
Copyright © 2024 - Odisha Television Limited All Rights Reserved.
LIVE TV
